

# Banu K Arun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5017402/publications.pdf>

Version: 2024-02-01

154  
papers

11,867  
citations

57758

44  
h-index

30087

103  
g-index

157  
all docs

157  
docs citations

157  
times ranked

16772  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet</i> , The, 2010, 376, 235-244.	13.7	1,584
2	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
3	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	7.0	710
4	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2015, 33, 3660-3667.	1.6	603
5	Clinical and Pathologic Characteristics of Patients With <i>BRCA</i> -Positive and <i>BRCA</i> -Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4282-4288.	1.6	535
6	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
7	Incidence and Outcome of <i>BRCA</i> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1082-1089.	7.0	487
8	Cancers associated with <i>BRCA1</i> and <i>BRCA2</i> mutations other than breast and ovarian. <i>Cancer</i> , 2015, 121, 269-275.	4.1	407
9	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
10	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
11	Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward. <i>Clinical Cancer Research</i> , 2006, 12, 3661-3697.	7.0	263
12	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
13	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
14	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
15	The role of COX-2 inhibition in breast cancer treatment and prevention. <i>Seminars in Oncology</i> , 2004, 31, 22-29.	2.2	180
16	Ductal Carcinoma in Situ: State of the Science and Roadmap to Advance the Field. <i>Journal of Clinical Oncology</i> , 2009, 27, 279-288.	1.6	151
17	Response to Neoadjuvant Systemic Therapy for Breast Cancer in <i>BRCA</i> Mutation Carriers and Noncarriers: A Single-Institution Experience. <i>Journal of Clinical Oncology</i> , 2011, 29, 3739-3746.	1.6	151
18	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant. <i>Journal of Clinical Oncology</i> , 2020, 38, 388-394.	1.6	151

#	ARTICLE	IF	CITATIONS
19	Breast tumours maintain a reservoir of subclonal diversity during expansion. <i>Nature</i> , 2021, 592, 302-308.	27.8	145
20	Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy. <i>Cancer Prevention Research</i> , 2010, 3, 1026-1034.	1.5	138
21	Expanding the Criteria for <i>BRCA</i> Mutation Testing in Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2010, 28, 4214-4220.	1.6	120
22	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
23	Contralateral prophylactic mastectomy. <i>Cancer</i> , 2004, 101, 1977-1986.	4.1	102
24	Outcome of triple-negative breast cancer in patients with or without deleterious <i>BRCA</i> mutations. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 145-153.	2.5	96
25	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
26	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
27	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i> - or <i>BRCA2</i> -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. <i>Clinical Cancer Research</i> , 2017, 23, 4066-4076.	7.0	87
28	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
29	The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in <i>BRCA1</i> and <i>BRCA2</i> mutant breast cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 262-268.	3.3	81
30	Clinical practice guidelines for <i>BRCA1</i> and <i>BRCA2</i> genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	2.8	81
31	Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious <i>BRCA</i> mutations at high risk of breast cancer. <i>Cancer</i> , 2011, 117, 3900-3907.	4.1	79
32	Women age ≥ 35 years with primary breast carcinoma. <i>Cancer</i> , 2005, 103, 2466-2472.	4.1	78
33	High incidence of germline <i>BRCA</i> mutation in patients with ER low/positive/PR low/positive/HER2/neu negative tumors. <i>Cancer</i> , 2015, 121, 3422-3427.	4.1	78
34	Inflammatory breast cancer: a proposed conceptual shift in the UICC/AJCC TNM staging system. <i>Lancet Oncology</i> , The, 2017, 18, e228-e232.	10.7	74
35	Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. <i>Cancer</i> , 2018, 124, 36-45.	4.1	70
36	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 698-712.	0.8	69

#	ARTICLE	IF	CITATIONS
37	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 407-416.	2.5	68
38	Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. <i>Annals of Surgical Oncology</i> , 2012, 19, 3777-3784.	1.5	67
39	Association between clinical characteristics and risk reduction interventions in women who underwent <i>BRCA1</i> and <i>BRCA2</i> testing. <i>Cancer</i> , 2006, 107, 2745-2751.	4.1	61
40	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 493-511.	3.2	58
41	Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. <i>Familial Cancer</i> , 2014, 13, 291-299.	1.9	56
42	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1207.	7.1	56
43	Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. <i>Obstetrics and Gynecology</i> , 2006, 108, 515-520.	2.4	55
44	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.9	54
45	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.5	47
46	Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. <i>Cancer Research</i> , 2015, 75, 4863-4875.	0.9	44
47	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	5.0	42
48	Cancer Incidence in First- and Second-Degree Relatives of <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Oncologist</i> , 2016, 21, 869-874.	3.7	41
49	BRCA mutation genetic testing implications in the United States. <i>Breast</i> , 2017, 31, 224-232.	2.2	41
50	USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 10-17.	2.0	39
51	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
52	Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 491-505.	1.8	33
53	High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. <i>Cancer Prevention Research</i> , 2009, 2, 122-127.	1.5	33
54	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32

#	ARTICLE	IF	CITATIONS
55	Perception of screening and risk reduction surgeries in patients tested for a <i>BRCA</i> deleterious mutation. <i>Cancer</i> , 2009, 115, 1598-1604.	4.1	31
56	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30
57	The search for the ideal SERM. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 681-691.	1.8	29
58	Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without $\epsilon$ CSF in Locally Advanced Breast Cancer: Long-Term Results. <i>Oncologist</i> , 2011, 16, 1527-1534.	3.7	29
59	A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi Anemia. <i>Molecular Cell</i> , 2020, 80, 1013-1024.e6.	9.7	29
60	Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. <i>Cancer Medicine</i> , 2017, 6, 2515-2522.	2.8	28
61	The <i>FANCM:p.Arg658*</i> truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28
62	Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials. <i>Clinical Cancer Research</i> , 2007, 13, 4943-4948.	7.0	27
63	Germline <i>BRCA1/BRCA2</i> mutations among high risk breast cancer patients in Jordan. <i>BMC Cancer</i> , 2018, 18, 152.	2.6	27
64	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
65	An international survey of surveillance schemes for unaffected <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 319-327.	2.5	26
66	Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. <i>Modern Pathology</i> , 2006, 19, 622-629.	5.5	25
67	Clinicopathologic characteristics of breast cancer in <i>BRCA</i> -carriers and non-carriers in women 35 years of age or less. <i>Breast</i> , 2014, 23, 770-774.	2.2	25
68	Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. <i>Cancer Medicine</i> , 2018, 7, 2718-2726.	2.8	25
69	Loss of FHIT Expression in Breast Cancer Is Correlated with Poor Prognostic Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1681-1685.	2.5	24
70	Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy. <i>Cancer Investigation</i> , 2010, 28, 554-559.	1.3	24
71	Predictive factors for <i>BRCA1/BRCA2</i> mutations in women with ductal carcinoma in situ. <i>Cancer</i> , 2012, 118, 1515-1522.	4.1	23
72	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23

#	ARTICLE	IF	CITATIONS
73	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. <i>BMC Cancer</i> , 2008, 8, 101.	2.6	22
74	Satisfaction with ovarian carcinoma risk reduction strategies among women at high risk for breast and ovarian carcinoma. <i>Cancer</i> , 2011, 117, 2659-2667.	4.1	22
75	Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing. <i>Annals of Surgical Oncology</i> , 2014, 21, 3466-3472.	1.5	22
76	Breast Cancer, BRCA Mutations, and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis. <i>Oncologist</i> , 2014, 19, 797-804.	3.7	21
77	Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. <i>Breast Journal</i> , 2015, 21, 260-267.	1.0	21
78	Validation of a personalized risk prediction model for contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 415-423.	2.5	19
79	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	6.4	19
80	Correlation of bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. <i>Cancer</i> , 2003, 98, 2554-2559.	4.1	18
81	Breast Cancer Prevention Trials: Large and Small Trials. <i>Seminars in Oncology</i> , 2010, 37, 367-383.	2.2	18
82	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
83	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
84	Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 101-109.	2.5	18
85	Patient characteristics associated with sleep disturbance in breast cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 2601-2611.	2.2	18
86	EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. <i>Nanomedicine</i> , 2019, 14, 2315-2338.	3.3	17
87	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 67-77.	2.5	16
88	Rates of BRCA1/2 mutation testing among young survivors of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 165-173.	2.5	16
89	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 299-306.	2.6	16
90	Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 545-556.	2.5	16

#	ARTICLE	IF	CITATIONS
91	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. <i>Cancers</i> , 2021, 13, 1656.	3.7	16
92	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
93	Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study. <i>Supportive Care in Cancer</i> , 2020, 28, 5821-5832.	2.2	15
94	Establishing a Program for Individuals at High Risk for Breast Cancer. <i>Journal of Cancer</i> , 2013, 4, 433-446.	2.5	14
95	BRCA mutations in women with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 466-474.	4.1	14
96	Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 518-524.	4.9	14
97	Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 5.	1.5	14
98	Service Delivery Model and Experiences in a Cancer Genetics Clinic for an Underserved Population. <i>Journal of Health Care for the Poor and Underserved</i> , 2015, 26, 784-791.	0.8	13
99	BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. <i>Oncologist</i> , 2015, 20, 593-597.	3.7	13
100	A two-stage approach to genetic risk assessment in primary care. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 375-383.	2.5	13
101	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR- $\beta$ . <i>Investigational New Drugs</i> , 2018, 36, 1103-1109.	2.6	13
102	Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing. <i>Annals of Surgical Oncology</i> , 2020, 27, 4613-4621.	1.5	13
103	Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. <i>Biomarkers in Cancer</i> , 2015, 7, BIC.S29716.	3.6	11
104	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 2299-2305.	4.1	11
105	Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings. <i>Journal of Genetic Counseling</i> , 2018, 27, 1482-1496.	1.6	11
106	Endothelin Converting Enzyme-1 Expression in Endometrial Adenocarcinomas. <i>Cancer Investigation</i> , 2001, 19, 779-782.	1.3	10
107	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.5	10
108	Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2-advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	2.8	10



#	ARTICLE	IF	CITATIONS
109	Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 46.	5.2	10
110	Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 303-307.	1.4	9
111	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	3.7	9
112	Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative. <i>Journal of Cancer</i> , 2015, 6, 610-615.	2.5	8
113	Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa002.	2.9	8
114	Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. <i>Oncologist</i> , 2017, 22, 655-666.	3.7	7
115	Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. <i>Cancer</i> , 2021, 127, 3605-3613.	4.1	7
116	Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer. <i>Cancer Prevention Research</i> , 2012, 5, 276-282.	1.5	6
117	Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. <i>Breast Journal</i> , 2020, 26, 1572-1582.	1.0	6
118	Multigene panel testing results in patients with multiple breast cancer primaries. <i>Breast Journal</i> , 2020, 26, 1337-1342.	1.0	6
119	Ductal Lavage and Risk Assessment of Breast Cancer. <i>Oncologist</i> , 2004, 9, 599-605.	3.7	5
120	Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. <i>Frontiers in Genetics</i> , 2016, 7, 71.	2.3	5
121	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2021, 274, e150-e159.	4.2	5
122	Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. <i>Cancer</i> , 2021, , .	4.1	5
123	Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. <i>Cancer Medicine</i> , 2022, 11, 1474-1483.	2.8	5
124	Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. <i>Journal of Cancer</i> , 2014, 5, 351-359.	2.5	4
125	Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. <i>Cancer Prevention Research</i> , 2017, 10, 641-650.	1.5	4
126	Should abbreviated breast MRI be compliant with American College of Radiology requirements for MRI accreditation?. <i>Magnetic Resonance Imaging</i> , 2020, 72, 87-94.	1.8	4



#	ARTICLE	IF	CITATIONS
127	Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. <i>Oncologist</i> , 2021, 26, e2086-e2089.	3.7	4
128	Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. <i>American Journal of Cancer Research</i> , 2016, 6, 981-95.	1.4	4
129	Helping Patients Understand and Cope with BRCA Mutations. <i>Current Oncology Reports</i> , 2022, 24, 733-740.	4.0	4
130	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	3.7	4
131	Active Disclosure of Secondary Germline Findings to Deceased Research Participantsâ€™ Personal Representatives: Process and Outcomes. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	3.0	3
132	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. <i>Breast Journal</i> , 2019, 25, 575-577.	1.0	3
133	Clinical implications of breast cancer tumor genomic testing. <i>Breast Journal</i> , 2020, 26, 1565-1571.	1.0	3
134	Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. <i>Cancer Prevention Research</i> , 2020, 13, 795-802.	1.5	3
135	Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: Opportunity for prompting family communication. <i>Journal of Community Genetics</i> , 2021, 12, 439-447.	1.2	3
136	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	5.2	3
137	The changing landscape of hereditary cancer genetic testing. <i>Cancer</i> , 2018, 124, 664-666.	4.1	2
138	Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer. <i>Cancers</i> , 2021, 13, 2050.	3.7	2
139	Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. <i>Hereditary Genetics: Current Research</i> , 2012, 01, .	0.1	2
140	Impact of a Genetic Evaluation Initiative to Increase Access to Genetic Services for Adolescent and Young Adults at a Tertiary Cancer Hospital. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 10, 296-302.	1.3	1
141	Perceptions of providerâ€™s epistemic authority in response to variant of uncertain significanceâ€related recommendations. <i>Journal of Genetic Counseling</i> , 2021, 30, 513-521.	1.6	1
142	Health care professionalsâ€™ attitudes toward cancer gene panel testing. <i>Breast Journal</i> , 2021, 27, 499-500.	1.0	1
143	Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	1
144	Epidemiology, Risk Factors, and Prevention. , 2016, , 57-87.		1

#	ARTICLE	IF	CITATIONS
145	Epidemiology, Risk Factors, and Prevention. , 2019, , 39-61.		1
146	Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study. Contemporary Clinical Trials, 2022, 113, 106662.	1.8	1
147	Reply to <i>BRCA2</i>â€associated pancreatic cancer and current screening guidelines. Cancer, 2015, 121, 3047-3047.	4.1	0
148	Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer, 2018, 124, 866-866.	4.1	0
149	Polygenic Risk Scores in Breast Cancer. Current Breast Cancer Reports, 2019, 11, 117-122.	1.0	0
150	Risk Management of Hereditary Breast Cancer. , 2008, , 93-105.		0
151	Ductal carcinoma <i>in situ</i>: how should we treat it?. Breast Cancer Management, 2013, 2, 245-256.	0.2	0
152	Medical Management of Breast Cancer in BRCA Mutation Carriers. , 2017, , 135-150.		0
153	Establishing a Program for Young Women at High Risk for Breast Cancer. , 2020, , 35-46.		0
154	Management of women at high risk for breast cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1 Suppl 1, S71-7.	4.9	0